USES SKYRIZI is a prescription medicine used to treat adults with: moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV …

May 8, 2025 · On June 18, 2024, the FDA approved SKYRIZI for the treatment of adult patients with moderately to severely active ulcerative colitis. This milestone expands the drug’s accessibility to …

Jun 18, 2024 · Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52 …

Jul 23, 2024 · As a treatment for ulcerative colitis, Skyrizi works by fighting the inflammation that can lead to symptoms of the disease.

Patients should be evaluated for tuberculosis (TB) prior to starting this medication, and should not be given Skyrizi® if there is active TB. If there is a hypersensitivity reaction or anaphylaxis occurs, …

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This approval …

SKYRIZI® is indicated for the treatment of moderately to severely active ulcerative colitis in adults. See Important Safety and Prescribing Information.

Jun 20, 2024 · The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works by blocking the …

Jun 18, 2024 · AbbVie has announced the US Food and Drug Administration (FDA) has approved risankizumab-rzaa (Skyrizi) for adults with moderately to severely active ulcerative colitis (UC), …

Risankizumab, sold under the brand name Skyrizi (/ skaɪˈrɪzi / sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and …